NASDAQ:MEIP MEI Pharma (MEIP) Stock Price, News & Analysis $3.06 -0.08 (-2.55%) (As of 10:47 AM ET) Add Compare Share Share Today's Range$3.06▼$3.0650-Day Range$2.78▼$3.7152-Week Range$2.73▼$7.87Volume339 shsAverage Volume53,203 shsMarket Capitalization$20.39 millionP/E Ratio0.78Dividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get MEI Pharma alerts: Email Address MEI Pharma MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside128.8% Upside$7.00 Price TargetShort InterestHealthy0.79% of Float Sold ShortDividend StrengthN/ASustainability-0.77Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom $3.22 to ($5.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.69 out of 5 starsMedical Sector206th out of 924 stocksPharmaceutical Preparations Industry82nd out of 426 stocks 3.0 Analyst's Opinion Consensus RatingMEI Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageMEI Pharma has only been the subject of 2 research reports in the past 90 days.Read more about MEI Pharma's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.79% of the float of MEI Pharma has been sold short.Short Interest Ratio / Days to CoverMEI Pharma has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MEI Pharma has recently increased by 636.36%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMEI Pharma does not currently pay a dividend.Dividend GrowthMEI Pharma does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMEI Pharma has received a 71.01% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for MEI Pharma is -0.77. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for MEI Pharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for MEIP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MEI Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.90% of the stock of MEI Pharma is held by insiders.Percentage Held by Institutions52.38% of the stock of MEI Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MEI Pharma's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for MEI Pharma are expected to decrease in the coming year, from $3.22 to ($5.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MEI Pharma is 0.78, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.08.Price to Earnings Ratio vs. SectorThe P/E ratio of MEI Pharma is 0.78, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 138.68.Price to Book Value per Share RatioMEI Pharma has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about MEI Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsWanted Dead: PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About MEI Pharma Stock (NASDAQ:MEIP)MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.Read More MEIP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MEIP Stock News HeadlinesAugust 19 at 2:14 AM | americanbankingnews.comMEI Pharma (NASDAQ:MEIP) Earns Buy Rating from Analysts at StockNews.comAugust 12, 2024 | finance.yahoo.comMEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic AlternativesAugust 22, 2024 | TradingTips (Ad)5 stocks that can double in 2024You still have time to access the 5 Stocks that Can Double in 2024 report for free.July 24, 2024 | msn.comLaidlaw & Co. Downgrades MEI Pharma (MEIP)July 22, 2024 | marketwatch.comMEI Pharma Considering Strategic Alternatives; CEO Urso Steps DownJuly 22, 2024 | markets.businessinsider.comMEI Pharma To Begin Evaluation Of Strategic Alternatives - Quick FactsJuly 22, 2024 | businesswire.comMEI Pharma to Consider Strategic AlternativesJuly 1, 2024 | investorplace.com7 Undervalued Biotech Stocks to Buy for Big-Time ReturnsAugust 22, 2024 | TradingTips (Ad)5 stocks that can double in 2024You still have time to access the 5 Stocks that Can Double in 2024 report for free.May 22, 2024 | money.usnews.comMEI Pharma IncMay 14, 2024 | businesswire.comGlancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)May 10, 2024 | investorplace.comMEIP Stock Earnings: MEI Pharma Beats EPS for Q3 2024May 9, 2024 | businesswire.comMEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational HighlightsApril 18, 2024 | insidermonkey.com5 Cheap Penny Stocks to Buy According to AnalystsApril 11, 2024 | msn.comMEI Pharma shelves plans for a second return of capitalApril 11, 2024 | businesswire.comMEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344April 11, 2024 | businesswire.comMEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer PatientsApril 10, 2024 | businesswire.comMEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology ForumSee More Headlines Receive MEIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today8/22/2024Next Earnings (Estimated)9/24/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MEIP Previous SymbolNASDAQ:MSHL CUSIPN/A CIK1262104 Webwww.meipharma.com Phone(858) 369-7100Fax302-655-5049Employees100Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+122.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$3.92 Trailing P/E Ratio0.80 Forward P/E Ratio0.98 P/E GrowthN/ANet Income$-31,840,000.00 Net MarginsN/A Pretax Margin39.18% Return on Equity48.32% Return on Assets28.13% Debt Debt-to-Equity RatioN/A Current Ratio6.17 Quick Ratio6.17 Sales & Book Value Annual Sales$66.75 million Price / Sales0.31 Cash FlowN/A Price / Cash FlowN/A Book Value$3.70 per share Price / Book0.85Miscellaneous Outstanding Shares6,663,000Free Float6,403,000Market Cap$20.92 million OptionableOptionable Beta0.86 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. David M. Urso B.A. (Age 60)Esq., J.D., CEO, President & Director Comp: $748.46kDr. Richard G. Ghalie M.D. (Age 66)MBA, Chief Medical Officer Comp: $627.76kMr. Justin J. File (Age 54)CFO & Corporate Secretary Ms. Yomara Gomez-NaidenSenior Vice President of Operations & QualityMs. Nicole Chyoko IidaVice President of Legal AffairsMs. Anne FreseChief People OfficerDr. Robert D. Mass (Age 70)Strategic Advisor Comp: $201.68kMr. David A. Walsey J.D.L.L.M., Senior Vice President of Corporate AffairsMore ExecutivesKey CompetitorsMagenta TherapeuticsNASDAQ:MGTACoya TherapeuticsNASDAQ:COYAIkena OncologyNASDAQ:IKNABenitec BiopharmaNASDAQ:BNTCGenenta ScienceNASDAQ:GNTAView All CompetitorsInsiders & InstitutionsAcadian Asset Management LLCSold 61,583 shares on 8/6/2024Ownership: 2.255%National Bank of Canada FIBought 10,000 shares on 8/3/2024Ownership: 0.495%Anson Funds Management LpBought 48,060 shares on 9/22/2023Total: $329,211.00 ($6.85/share)Anson Funds Management LpBought 120,000 shares on 9/20/2023Total: $721,200.00 ($6.01/share)View All Insider TransactionsView All Institutional Transactions MEIP Stock Analysis - Frequently Asked Questions How have MEIP shares performed this year? MEI Pharma's stock was trading at $5.80 at the beginning of the year. Since then, MEIP shares have decreased by 47.2% and is now trading at $3.06. View the best growth stocks for 2024 here. How were MEI Pharma's earnings last quarter? MEI Pharma, Inc. (NASDAQ:MEIP) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($2.60) earnings per share for the quarter, meeting the consensus estimate of ($2.60). The business had revenue of $13.39 million for the quarter, compared to analysts' expectations of $9.98 million. When did MEI Pharma's stock split? MEI Pharma shares reverse split before market open on Monday, April 17th 2023. The 1-20 reverse split was announced on Monday, April 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are MEI Pharma's major shareholders? MEI Pharma's top institutional investors include Acadian Asset Management LLC (2.25%) and National Bank of Canada FI (0.50%). Insiders that own company stock include Anson Funds Management Lp and Charles V Baltic III. View institutional ownership trends. How do I buy shares of MEI Pharma? Shares of MEIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of MEI Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that MEI Pharma investors own include Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), SCYNEXIS (SCYX) and OPKO Health (OPK). This page (NASDAQ:MEIP) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredThe #1 A.I. Crypto You Don’t Own (YET!)Markets are volatile right now—stocks, cryptos, you name it. But here's a crucial fact everyone is missing:...Crypto 101 Media | SponsoredThis One stock is all you need...What if you could ignore 99% of the stock market... And retire on just ONE ticker?Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MEI Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MEI Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
